Hims & Hers – The US Telemedicine Provider Raises Forecast Yet Still Falls!

Hims significantly raises its revenue forecast – yet the stock still falls. The culprit is a loss of 37 cents instead of the expected 6 cents per share, caused by the costly shift away from high-margin GLP-1 imitators. The new hope is called peptides: Hims plans to enter this market later this year. The catch: Their benefits are hardly proven, and a recent recall advises caution. Forecast strong, loss weak Hims & Hers raises its revenue forecast for the full year to $3.1 to $3.3 billion, up from a previous maximum of $3 billion, and is...